More medtech IPOs axed
This article was originally published in Clinica
Executive Summary
Two further medical device firms have terminated their IPOs on the Nasdaq stock exchange, bringing the total number of listing cancellations for medtech firms so far this month to four. Organ transportation firm TransMedics (Andover, Massachusetts) and healthcare information technology specialist Epocrates (San Mateo, California) both filed withdrawal requests with the Securities and Exchange Commission on December 12. Both firms cited unfavourable market conditions as the reason for the withdrawals. Earlier this month, ear, nose and throat company Acclarent and molecular diagnostics firm Osmetech also cancelled their IPOs (see Clinica No 1329, p 17).